Moderna seeks US approval for 94.1% effective vaccine

US

Moderna has said it is filing for regulatory approval in the US, and that its vaccine trials have shown no serious safety concerns.

The US-based company has also said its vaccine was 94.1% effective, with 100% efficacy against severe COVID-19 in its phase three trial.

Efficacy was consistent across age, race and ethnicity, as well as gender, the company has said.

Speaking to Reuters news agency, chief medical officer Dr Tal Zaks said: “We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it.”

Products You May Like

Articles You May Like

Government calls on industry to introduce voluntary levy on stadium and arena tickets to support grassroots venues | UK News
Harris Leading Trump In Iowa Shows Something Big Happening In The Midwest
Best T-Shirts for Men: The Internet’s Favorites Ranked
Season 2 of Nathan Fielder’s The Rehearsal Premieres in 2025
3 Secret Ways Trump Won